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SUMMARY
Disorders of sex development (DSD) involve several conditions that result from abnormalities 
during gonadal determination and differentiation. Some of these disorders may manifest at 
birth by ambiguous genitalia; others are diagnosed only at puberty, by the delayed onset of se-
condary sexual characteristics. Sex determination and differentiation in humans are processes 
that involve the interaction of several genes such as WT1, NR5A1, NR0B1, SOX9, among others, 
in the testicular pathway, and WNT4, DAX1, FOXL2 and RSPO1, in the ovarian pathway. One of 
the major proteins in mammalian gonadal differentiation is the steroidogenic nuclear receptor 
factor 1 (SF1). This review will cover some of the most recent data on SF1 functional roles and 
findings related to mutations in its coding gene, NR5A1. Arq Bras Endocrinol Metab. 2011;55(8):607-12
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SUMÁRIO
Os distúrbios do desenvolvimento sexual (DDS) envolvem várias condições que resultam de 
anormalidades que podem acontecer tanto na determinação como durante a diferenciação 
gonadal. Algumas dessas doenças podem se manifestar ao nascimento principalmente por ge-
nitália ambígua, outras são diagnosticadas apenas na puberdade por atraso no aparecimento 
de características sexuais secundárias. A determinação e a diferenciação do sexo em seres hu-
manos são processos que envolvem interações entre vários genes nas vias testicular, tais como 
NR5A1, NR0B1, WT1, SOX9, entre outros, e ovariana, tais como WNT4, DAX1, FOXL2 e RSPO1. 
Uma das principais proteínas na diferenciação gonadal de mamíferos é o fator esteroidogênico 
e receptor nuclear 1 (SF1). Esta revisão cobrirá alguns dos dados mais recentes sobre os papéis 
funcionais de SF1 e as últimas descobertas relacionadas a mutações em seu gene, NR5A1. Arq 
Bras Endocrinol Metab. 2011;55(8):607-12
Descritores
Fator esteroidogênico 1; gene NR5A1; doenças do desenvolvimento sexual
The presence or absence of the Y chromosome in the karyotype of most mammals, including hu­
mans, is linked, respectively, to the processes of male 
and female sex determination and differentiation (1,2). 
Sex development is classically divided into three stages: 
determination, which is chromosomally established at 
fertilization; differentiation of the gonads from undif­
ferentiated embryonic structures into testes or ovaries; 
and secondary sexual differentiation, which is the res­
ponse of innumerous tissues to hormones produced by 
either gonads to complete sexual maturation during 
puberty (3). Disorders of sex development (DSD) in­
volve several conditions that result from abnormalities 
in one of the three stages. Some of these disorders may 
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manifest at birth by ambiguous genitalia; others are di­
agnosed only at puberty by delayed onset of secondary 
sexual characteristics (4,5). In cases of newborns with 
ambiguous genitalia, the definition of appropriate sex is 
urgent, because it generally requires a series of surgical 
procedures, hormone therapy and counseling (5). The 
understanding of the intricate processes that involve sex 
determination and differentiation has been a challenge 
for physicians and scientists in general.
DSD are characterized by incomplete or disordered 
gonadal or genital development, leading to divergen­
ces between genetic sex, gonadal sex and phenotypic 
sex, specially in individuals with 46,XY karyotype (6,7). 
These cases present female or ambiguous genitalia that 
may vary from mild to severe hypospadias, with or wi­
thout penoscrotal chordee, dysgenetic testes, reduced 
or null sperm production, and Müllerian structures that 
may be absent or present as fully developed uterus and 
fallopian tubes (8). In cases of 46,XY DSD, gonadal 
dysgenesis refers to a set of abnormalities characterized 
by dysgenetic gonads as a result of failures in the ex­
pression or function of genes involved in testicular de­
velopment (4,9). Dysgenetic gonads are mainly formed 
by fibrous tissue without hormonal function that is not 
able to produce gametes; whereas dysgenetic testes are 
associated with abnormalities in the differentiation of 
the Wolffian ducts, in external genitalia virilization, and 
in the regression of Müllerian ducts (10).
Gonadal dysgenesis may be classified as pure (com­
plete), partial (incomplete) or mixed dysgenesis (11). 
Complete gonadal dysgenesis (CGD) is characterized 
by phenotypically female individuals without genital 
ambiguity, and presence of dysgenetic gonads, and nor­
mal Müllerian derivatives. It may occur in individuals 
with normal karyotypes, 46,XX or 46,XY (12). Indivi­
duals with XY CGD are prone to developing gonadal 
tumors (13). Conversely, incomplete gonadal dysgene­
sis (DGI) is characterized by individuals 46,XY without 
mosaicism, with partial testicular differentiation, deri­
vatives of Müllerian ducts and genital ambiguity. Usu­
ally, seminiferous tubules are present and associated 
with areas similar to ovarian stroma. Internal genitalia 
consists of derivatives of both Wolffian and Müllerian 
ducts (12). The presence of a second cell lineage pre­
senting 45,X in the karyotype characterizes mixed go­
nadal dysgenesis (14). 
After two decades of the identification of SRY gene 
as the sex­determining region on the Y chromosome 
responsible for initiating male development, it is well 
known that sex determination and differentiation in 
humans are processes that involve the interaction of 
several genes, such as WT1, NR5A1, NR0B1, SOX9, 
among others, in the testicular pathway; and WNT4, 
DAX1, FOXL2 and RSPO1, in the ovarian pathway 
(8,15). Figure 1 illustrates the main steps and genes 
involved in gonadal differentiation that result in male 
and female characteristics.
One of the major proteins in mammalian gonadal 
differentiation is the steroidogenic nuclear receptor fac­
tor 1 (SF1) now known as nuclear receptor subfamily 5 
group A member 1 (NR5A1 [MIM 184757]). The hu­
man SF1 protein is formed by 461 amino acids and is a 
member of the orphan nuclear receptor family, conside­
red the main regulator of enzymes involved in adrenal 
and gonadal steroidogenesis, and is expressed in undi­
fferentiated gonads before SRY (16). The expression of 
NR5A1 gene, which encodes SF1 protein, is necessary 
at three stages throughout testis determination and di­
fferentiation: in the formation of bipotential gonads; 
in the Sertoli cells, to regulate the expression of anti­
­Müllerian hormone gene (AMH); and in the Leydig 
cells, to regulate the expression a number of steroid 
hormones (17,18). Therefore, it plays an important 
role in the expression of male specific genes. In female 
development, it is also actively present and participates 
in different steps of ovarian development and function 
(19). The wide range of action of this protein became 
evident after observations in mice, showing that the 
gene is expressed very early in the urogenital ridge, and 
acts later on in the development of the adrenals, gona­
ds, pituitary, and ventromedial hypothalamus (20,21).
SF1 was first isolated in 1992 during the search for 
elements that regulate the proximal promoter region 
of the cytochrome P450 21­hydroxylase enzyme (22). 
SF1 protein is highly expressed in steroidogenic tissues, 
such as gonads, adrenals, and placenta, and regulates 
almost all the enzymes related to this process (23). It 
is essential not only in adrenal and gonadal develop­
ment and sex differentiation, but also plays important 
physiological roles in the central nervous system (21). 
As illustrated in figure 1, after testicular determina­
tion, SF1 regulates the expression of anti­Mülllerian 
hormone in Sertoli cells, which leads to regression of 
Müllerian structures during fetal development (18). In 
Leydig cells, SF1 activates the expression of steroidoge­
nic enzymatic system, resulting in virilization of exter­
nal genitalia and testicular descent (24,25). In females, 
SF1 is expressed in ovarian theca cells and granulosa 
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Figure 1. Sexual development cascade [adapted from Swain (1) and 
Biason-Lauber (2)]. The most important proteins in male and female 
pathways are shown in the figure. WT1 and SF1 are expressed in the 
bipotential gonad that develops into an ovary under the action of LIM1, 
FOXL2, RSPO1 and WNT4, whereas in the presence of SRY, a testis 
develops with additional action of SOX9, DHH and DMRT1, among others. 
In the testis, germ cells, Sertoli cells, and Leydig cells differentiate. SF1-
regulated production of AMH, Insl3, and testosterone induce the 
differentiation of the male-specific internal and external genitalia. In the 
ovaries, beside germ cells, there are follicle cells and theca cells, in which 
SF1-regulation is also important.
cells, early in folliculogenesis (26). In addition, SF1 is 
the main regulator of cholesterol metabolism in steroi­
dogenic cells, stimulating the expression of almost all 
factors involved in the mobilization of cholesterol and 
steroid hormone biosynthesis (27). 
NR5A1 is an autosomal gene located at 9q33 
(OMIM 184757). It expands over 30 kb of genomic 
DNA divided into one non­coding exon followed by six 
coding exons (28). The structure of human SF1 pro­
tein includes: a DNA­binding domain (DBD) contai­
ning two zinc fingers, a ligand­binding domain (LBD), 
two functional activation domains (AF­1 and AF­2); an 
accessory region, and a hinge region. The first zinc fin­
ger contains a proximal (P box) region, that is involved 
in nuclear receptor specific recognition of DNA target 
sequences (29). The region contains an accessory box 
that stabilizes DNA binding. The hinge region is im­
portant for SF1 transcriptional activity (30). Moreover, 
unlike most nuclear receptors, SF1 binds DNA as a 
monomer with high affinity for the region 5’YCAA­
GGYCR’3 (where Y = T / C, R = G / A) (31). As a 
member of the NR5A subfamily, it has the DBD ex­
tended by a FTZ­F1 box, which is important for DNA 
anchoring. This box contains a T­box that supports an 
A­box that, in turn, interacts co­operatively with the P­
­box in the first Zn­finger of the DBD, and defines the 
specificity of the monomeric DNA binding (20).
Similar to the great majority of transcription factors, 
the activation of SF1 transcriptional activity requires 
the interaction with other proteins through its protein 
activation domains (20). Furthermore, transcriptional 
activity of SF­1 is modified by post­translational modi­
fications such as phosphorylation/dephosphorylation, 
acetylation and SUMOylation (20,21). Its expression 
is precisely regulated in a time­ and tissue­dependent 
manner by promoters formed through alternative non­
coding exons 1 (32,33), upstream stimulatory factors 
1 and 2 (USF1, USF2) (34), interactions at the ba­
sal promoter region with different regulatory elements 
(20), and methylation at the basal promoter region, as 
well as at intronic enhancers (35).
Several studies have shown that the NR5A1 gene is 
highly conserved among species, and the overall ami­
no acid similarity between mice and humans is 95%. 
Homozygous mutations that inactivate SF1 in mice are 
manifested by the absence of adrenal and gonadal de­
velopment, the absence of pituitary gonadotropins and 
structural changes in the ventral and median hipota­
lamus regions. Nr5A1 gene deletions in such animals 
cause complete adrenal and gonadal agenesis, defects in 
virilization and retention of Müllerian ducts in XY ani­
mals (36,37). Abnormalities in the pituitary and in the 
brain, specifically in the ventromedial hypothalamus, 
are also attributed to the Nr5A1 deletion (21).
Sequencing NR5A1 gene of an XY female reve­
aled the heterozygosity for the missense mutation 
p.Gly35Glu (38). This was the first mutation described 
in humans, and the reported patient presented primary 
adrenal insufficiency, complete gonadal dysgenesis, and 
Müllerian duct persistence. It was a de novo heterozygous 
mutation, leading to an amino acid substitution in the 
first zinc finger P­box DNA­binding region, severely 
affecting SF1 function (38,39). A homozygous patient 
with similar phenotype had been subsequently described 
as carrying the p.Arg92Gln mutation located in the A­
­box region. This inherited mutation caused partial loss 
of SF1 function in vitro, what explained that hetero­
zygous carriers were normal (40). Several studies sho­
wed an haploinsufficiency effect caused by inactivating 
mutations in the NR5A1 gene in 46,XY heterozygous 
individuals with gonadal dysgenesis and without adrenal 
failure (41­43). Actually, mutations in the NR5A1 gene 
may be more frequent in patients with gonadal dysge­
nesis without adrenal insufficiency than in patients with 
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both gonadal dysgenesis and adrenal insufficiency (43). 
Considering the type of each mutation already identified 
in NR5A1, it is difficult to establish a direct phenotype­
­genotype correlation (Figure 2). If we consider that 
there is a dosage effect, it is difficult to understand why 
all patients heterozygous for severe nonsense mutations 
occurring in the first and second coding exons, as well as 
other frameshift mutations that are considered to under­
go mRNA nonsense­mediated decay, do not present the 
severe phenotype, including adrenal insufficiency. Ne­
vertheless, heterozygous mutations such as p.Glu11Ter, 
p.Cis16Ter and p.Glu51ArgfsX23 were identified in pa­
tients with, respectively, XY DSD and severe penoscrotal 
hypospadia, and cryptorchidism without adrenal insu­
fficiency. Most mutations were found in heterozygous 
patients either as de novo mutations or as inherited from 
a non­affected parent, indicating a dominant inheritan­
ce with different degree of penetrance. It is interesting 
to note that from the nine mutations identified in XY 
DSD and in XX primary ovarian insufficiency, eight are 
nonsense or frameshift mutations (Figure 2), and most 
of them had been inherited. Conversely, there are two 
cases of homozygosity for inherited mutations enabling 
the conclusion that, in those cases, the mutation was 
transmitted in a recessive manner. The p.Arg92Gln 
described above is one, and the other is p.Asp293Asn, 
which was found segregating in a family, and resulted 
in three different phenotypes: XX primary ovarian in­
sufficiency, XY incomplete gonadal dysgenesis, and XY 
complete gonadal dysgenesis (44,45). 
 Many studies have shown that variations in the NR5A1 
may be associated not only with gonadal dysgenesis and 
adrenal failure, but also with hypospadias, anorchia, male 
infertility, and premature ovarian failure, affecting both 
Figure 2. Schematic overview of SF-1 and locations of each NR5A1 mutation [adapted from Hoivik and cols. (20) and Ferraz-de-Souza and cols. (46)]. The 
main functional domains of the SF1 protein are shown, indicating the position of the DNA-binding domain (DBD) and the ligand-binding domain (LBD). 
FTZ-F1 domain that stabilizes protein binding to DNA is also illustrated. The two zinc fingers (Zn I, Zn II) of the DBD are highlighted on top. The P-box within 
zinc finger I is indicated by a dashed square. The hinge region between DNA- and ligand-binding domains is important for stabilizing the ligand-binding 
domains, and interacts with other proteins that control SF1 transcriptional activity. Post-translational modifications such as acetylation (in the DBD and 
Ftz-F1), SUMOylation in the residue K119 and K194, and phosphorylation in the residue S203 within the hinge region are indicated above. AF-1 and AF-2; 
activation function domains 1 and 2, NLS; nuclear localization signal, Pro-rich; proline-rich region, Ftz-F1; Fushi-tarazu factor-1 box, P/T/A; “DNA binding 
boxes”, Zn I and Zn II; zinc fingers I and II are also denoted. Underlined mutations were detected in both 46,XX and 46,XY individuals. All changes were 
present in heterozygosis, except those denoted in bold. AI, adrenal insufficiency; DSD, disorder of sex development; POI, primary ovarian insufficiency; 
SPH, severe penoscrotal hypospadia; Crypt, cryptorchidism; MI, male infertility; BAM, bilateral anorchia with microphallus. Mutations in parenthesis are 
the presumed consequence on the protein sequence of nucleotide insertions or deletions. Missense mutations are in black; nonsense and frameshift 
mutations are in red. Mutations in green and blue are, respectively, an in-frame deletion and an insertion that eliminates the natural stop codon.
SF1 and disorders of sex development
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46,XY and 46,XX individuals. In some cases, it may be also 
associated with adrenal tumors and endometriosis (46).
The identification of NR5A1 nucleotide changes 
in women with primary ovarian failure clearly indica­
tes that SF1 is indeed a key factor in the development 
and function of ovaries in humans (44), although it 
was considered before that NR5A1 mutations might 
not interfere with ovarian development (47). SF1 fai­
lure may affect the ovary at several levels: reducing the 
number of germ cells, damaging stroma integrity, and 
causing abnormal folliculogenesis. Phenotypic varia­
bility is verified for either 46,XY or 46,XX individuals 
carrying NR5A1 mutations within families, proba­
bly as a result of multifunctional roles of SF1 protein 
(8,15,44,45,48). Another example of a mutated SF1 
allele affecting both male and female development 
is the allele carrying the mutations p.Gly123Ala and 
p.Pro129Leu within the SF1 hinge region, which has 
been associated to either ovarian insufficiency or male 
infertility (44,49). In addition, p.Gly146Ala, also loca­
ted in the hinge region, has been described as a missen­
se associated with micropenis and cryptorchidism (50).
Finally, all the molecular studies reported so far in­
dicate different clinical manifestations for different nu­
cleotide changes in the NR5A1 gene. Bilateral anorchia 
or testicular regression, in addition to all other manifes­
tations, was reported as a result of p.Val355Met muta­
tion in one out of 24 children evaluated (51). Howe­
ver, a recent study involving 26 patients with the same 
condition did not reveal any mutation (52), indicating 
that NR5A1 mutation might be not a frequent cause 
of anorchia. It can be inferred from all data reported 
so far that mutations in the NR5A1 gene are more fre­
quent than in the SRY gene in cases of 46,XY DSD 
(53). However, more research on mutation screenin­
gs is necessary to indicate NR5A1 gene mutations as 
frequent causes of either primary or premature ovarian 
failure without adrenal insufficiency.
The findings reviewed here indicate a complex ex­
pressivity of the phenotype, penetrance, and modes 
of inheritance of NR5A1 mutations, and suggest that 
more research has to be done to figure out how NR5A1 
mutations correlate with different phenotypes, whether 
and how other genes modulate their expressivity, and 
to identify these genes for each affected phenotype.
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